Press release
Follicular Lymphoma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Mab Works, AstraZeneca, ADC Therapeutics,
Follicular Lymphoma Pipeline Insight
Follicular Lymphoma Pipeline constitutes 50+ key companies continuously working towards developing 55+ Follicular Lymphoma treatment therapies, analyzes DelveInsight.
Follicular Lymphoma Overview:
Follicular lymphoma (FL) is an indolent B-cell non-Hodgkin lymphoma (NHL), accounting for 20-30% of all NHL cases. While not typically curable, FL is often managed as a chronic condition, with patients living for many years post-diagnosis. FL originates from germinal center B-cells and is characterized by abnormal proliferation of malignant B-cells, leading to lymph node enlargement, spleen or bone marrow involvement, and potential spread to other tissues and organs.
The hallmark genetic mutation in FL is the translocation t(14;18)(q32;q21), causing overexpression of BCL2, an anti-apoptotic protein. About 5% of cases involve deregulated BCL6, critical for germinal center formation and transcription regulation. Other implicated genes include those related to cell cycle arrest, such as p21 and p16.
"Follicular Lymphoma Pipeline Insight 2025 [https://www.delveinsight.com/report-store/follicular-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Follicular Lymphoma Therapeutics Market.
Key Takeaways from the Follicular Lymphoma Pipeline Report
*
DelveInsight's Follicular Lymphoma pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Follicular Lymphoma treatment.
*
In August 2025, the company plans to submit a supplemental Biologics License Application (sBLA) for tafasitamab by the end of the year. This application targets the treatment of patients with follicular lymphoma (FL) who have not responded to at least one prior systemic anti-CD20 immunotherapy or chemo-immunotherapy, based on positive Phase III trial results.
*
In June 2025, a consortium led by Eugene Private Equity and Korea Development Bank Private Equity announced the acquisition of an 80% stake in South Korean vaccine manufacturer Boryung Biopharma Co. for 320 billion won (approximately USD 231 million).
*
In February 2025, Incyte revealed it had entered into an asset purchase agreement with MorphoSys AG, granting Incyte exclusive global rights to tafasitamab. Following this agreement, Incyte will assume full responsibility for U.S. commercialization and clinical development, with MorphoSys no longer eligible for milestone payments, profit shares, or royalty payments.
*
Key Follicular Lymphoma companies such as Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharma, LTZ Therapeutics, Hutchmed, Regeneron Pharmaceuticals, Pfizer, InnoCare Pharma, TriSalus Life Sciences, BeiGene, and others are evaluating new drugs for Follicular Lymphoma to improve the treatment landscape.
*
Promising Follicular Lymphoma pipeline therapies in various stages of development include MIL62, AZD0486, Abexinostat, ABBV-319, NX-2127, and others.
Follicular Lymphoma Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Follicular Lymphoma Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Follicular Lymphoma treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Follicular Lymphoma market.
Download our free sample page report on Follicular Lymphoma pipeline insights [https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Follicular Lymphoma Emerging Drugs
*
MIL62: MAB WORKS
*
AZD0486: AstraZeneca
*
Abexinostat: Xynomic Pharmaceuticals
*
ABBV-319: AbbVie
*
NX-2127: Nurix Therapeutics, Inc.
Follicular Lymphoma Companies
Over 50 prominent companies are actively working on developing therapies for Follicular Lymphoma. Among these, MAB WORKS and AstraZeneca have drug candidates in the most advanced stage of development, specifically Phase III trials.
DelveInsight's report covers around 22+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Follicular Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Follicular Lymphoma Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Follicular Lymphoma Therapies and Key Companies: Follicular Lymphoma Clinical Trials and advancements [https://www.delveinsight.com/report-store/follicular-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Follicular Lymphoma Pipeline Therapeutic Assessment
- Follicular Lymphoma Assessment by Product Type
- Follicular Lymphoma By Stage
- Follicular Lymphoma Assessment by Route of Administration
- Follicular Lymphoma Assessment by Molecule Type
Download Follicular Lymphoma Sample report to know in detail about the Follicular Lymphoma treatment market @ Follicular Lymphoma Therapeutic Assessment [https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Follicular Lymphoma Current Treatment Patterns
4. Follicular Lymphoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Follicular Lymphoma Late-Stage Products (Phase-III)
7. Follicular Lymphoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Follicular Lymphoma Discontinued Products
13. Follicular Lymphoma Product Profiles
14. Follicular Lymphoma Key Companies
15. Follicular Lymphoma Key Products
16. Dormant and Discontinued Products
17. Follicular Lymphoma Unmet Needs
18. Follicular Lymphoma Future Perspectives
19. Follicular Lymphoma Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Follicular Lymphoma Pipeline Reports Offerings: https://www.delveinsight.com/report-store/follicular-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=follicular-lymphoma-clinical-and-nonclinical-studies-key-companies-therapeutic-assessment-emerging-therapies-treatment-algorithm-and-pipeline-analysis-mab-works-astrazeneca-adc-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Follicular Lymphoma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Mab Works, AstraZeneca, ADC Therapeutics, here
News-ID: 4080529 • Views: …
More Releases from ABNewswire
Essential Thrombocythemia Market Poised for Strong Growth Amid Promising Clinica …
The essential thrombocythemia market is on a growth trajectory, driven by increasing diagnosis rates, aging population demographics, and emerging targeted therapies to address this rare blood disorder. Leading pharmaceutical companies like pharma&, PharmaEssentia, Merck, MorphoSys, Step Pharma, AOP Orphan Pharmaceuticals AG, Incyte Corporation, Janssen Research & Development, and others are driving innovation, shaping the essential thrombocythemia market's expansion through 2034.
DelveInsight's "Essential Thrombocythemia - Market Insight, Epidemiology And Market Forecast -…
Frontotemporal Dementia Clinical Trials, Companies, Therapeutic Assessment, Ther …
DelveInsight's, "Frontotemporal Dementia - Pipeline Insight, 2025" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Frontotemporal Dementia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Frontotemporal Dementia Pipeline constitutes 15+ key companies continuously working towards…
Excessive Daytime Sleepiness Clinical Trials, Companies, Therapeutic Assessment, …
DelveInsight's, "Excessive Daytime Sleepiness - Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Excessive Daytime Sleepiness pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Excessive Daytime Sleepiness Pipeline constitutes 10+ key companies…
Corneal Endothelial Dystrophy Clinical and Non-Clinical Studies, Key Companies, …
DelveInsight's, "Corneal Endothelial Dystrophy - Pipeline Insight, 2025," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Corneal Endothelial Dystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Corneal Endothelial Dystrophy Pipeline constitutes 4+ key companies…
More Releases for Follicular
Follicular Lymphoma Treatment Market Entry Strategies, Countermeasures of Econom …
The exclusive research report on 'Follicular Lymphoma Treatment Market' now available with 𝐂𝐨𝐡𝐞𝐫𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, offers a detailed analysis of the factors influencing the global business sphere. This report also provides precise information pertaining to market size, commercialization aspects and revenue estimation of this business. The report further elucidates the status of leading industry players thriving in the competitive spectrum of the Follicular Lymphoma Treatment Market.
The research report incorporates a…
Follicular Unit Extraction (FUE) Systems Market 2021 | Detailed Report
ReportsnReports publishes the report titled Follicular Unit Extraction (FUE) Systems that presents a 360-degree overview of the market under one roof. The report is developed with the meticulous efforts of an enthusiastic and experienced team of experts, analyts, and researchers that makes the report a valuable asset for stakeholders to make robust decisions. This report also provides an in-depth overview of product type, specification, technology, and production analysis considering vital…
Follicular Lymphoma Drugs Market 2021 | Detailed Report
Follicular Lymphoma Drugs Market Forecasts report provided to identify significant trends, drivers, influence factors in global and regions, agreements, new product launches and acquisitions, Analysis, market drivers, opportunities and challenges, risks in the market, cost and forecasts to 2027.
Get Free Sample PDF (including full TOC, Tables and Figures) of Follicular Lymphoma Drugs Market @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=4460211
The report provides a comprehensive analysis of company profiles listed below:
- Genentech (Roche)
- Bristol-Myers Squibb
-…
Hair Transplant Market by Surgery Type (Follicular Unit Strip Surgery, Follicula …
The Global Hair Transplant Market provides industry overview in terms of revenue (in US$ Mn). Furthermore, the report includes drivers, restraints, trends and opportunity of the Hair transplant market and their impact on each country during the forecast period.
Hair Transplantation is a surgical technique used to treat alopecia or baldness. Hair transplantation market report is segmented as surgical and non- surgical technique. The Surgical techniques include Robotic hair transplantation, follicular…
Follicular Lymphoma Treatment Market: Industry Size, Share, Growth, Forecasts 20 …
MarketResearchReports.Biz announces addition of new report "Follicular Lymphoma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025" to its database.
The objectives of this study are as follows:
To define, describe, and forecast the "Follicular Lymphoma Treatment" market by type, application, component, delivery model, end user, and region
To provide detailed information regarding major factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges)
To analyze micromarkets with…
A Comprehensive Study exploring Follicular Lymphoma Treatment Market
HTF MI recently introduced Global Follicular Lymphoma Treatment Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. At present, the market is developing its presence and some of the key players from the complete study are Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Celldex Therapeutics, Inc., Celltrion, Inc., Cellular Biomedicine Group, Inc., Coherus BioSciences, Inc., CTI BioPharma Corp.,…
